- Home
- VRAR vs RANI Comparison
VRAR vs RANI Comparison
Compare VRAR & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRAR
- RANI
- Stock Information
- Founded
- VRAR 2016
- RANI 2012
- Country
- VRAR United States
- RANI United States
- Employees
- VRAR N/A
- RANI N/A
- Industry
- VRAR Retail: Computer Software & Peripheral Equipment
- RANI Medicinal Chemicals and Botanical Products
- Sector
- VRAR Technology
- RANI Health Care
- Exchange
- VRAR Nasdaq
- RANI Nasdaq
- Market Cap
- VRAR 29.1M
- RANI 24.2M
- IPO Year
- VRAR 2021
- RANI 2021
- Fundamental
- Price
- VRAR $1.62
- RANI $1.89
- Analyst Decision
- VRAR Strong Buy
- RANI Strong Buy
- Analyst Count
- VRAR 1
- RANI 6
- Target Price
- VRAR $2.62
- RANI $8.67
- AVG Volume (30 Days)
- VRAR 263.7K
- RANI 44.8M
- Earning Date
- VRAR 11-13-2025
- RANI 11-13-2025
- Dividend Yield
- VRAR N/A
- RANI N/A
- EPS Growth
- VRAR N/A
- RANI N/A
- EPS
- VRAR N/A
- RANI N/A
- Revenue
- VRAR $10,527,925.00
- RANI $1,200,000.00
- Revenue This Year
- VRAR $15.29
- RANI N/A
- Revenue Next Year
- VRAR $44.54
- RANI N/A
- P/E Ratio
- VRAR N/A
- RANI N/A
- Revenue Growth
- VRAR 19.58
- RANI N/A
- 52 Week Low
- VRAR $0.50
- RANI $0.39
- 52 Week High
- VRAR $7.00
- RANI $3.87
- Technical
- Relative Strength Index (RSI)
- VRAR 52.41
- RANI 63.52
- Support Level
- VRAR $1.47
- RANI $1.76
- Resistance Level
- VRAR $1.71
- RANI $3.87
- Average True Range (ATR)
- VRAR 0.11
- RANI 0.48
- MACD
- VRAR 0.00
- RANI 0.09
- Stochastic Oscillator
- VRAR 59.50
- RANI 42.27
About VRAR The Glimpse Group Inc.
The Glimpse Group Inc is a diversified Virtual and Augmented Reality platform company, comprised of multiple VR and AR software and services companies, and designed with the specific purpose of cultivating companies in the emerging VR/AR industry.
About RANI Rani Therapeutics Holdings Inc.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.